Supplement

CONCLUSIONS: pET is associated with significant improvement in PR
and trend towards increase IR and OP versus regular ET or DET. Personalization
of the endometrial factor in the diagnostic work-up of the infertile
couple must be considered.
Supported by: Igenomix. On behalf of the ERA RCT Consortium. ClinicalTrials.gov
NCT 01954758.
O-116 Tuesday, October 18, 2016 11:30 AM
DIMINISHED BUT NOT DECLINING: LONGITUDINAL
ANDROGEN PRODUCTION AND FOLLICULAR MEASURES OF
OVARIAN RESERVE IN CANCER SURVIVORS COMPARED TO
HEALTHY CONTROLS. K. Cameron, a M. D. Sammel, b
M. M. Prewitt, c M. E. Lynch, d C. Gracia. a a University of Pennsylvania, Philadelphia,
PA; b Biostatistics and Epidemiology, Univ. of Pennsylvania, Perelman
School of Medicine, Philadelphia, PA; c Obstetrics and Gynecology,
University of Pennsylvania School of Medicine, Philadelphia, PA; d University
of Pennsylvania School of Medicine, Ardmore, PA.
OBJECTIVE: Recent studies have examined levels and the rates of
change of follicular measures of ovarian reserve in cancer survivors over
time. No data exist examining androgen production in this population,
which is important for folliculogenesis and sexual health. This study sought
to examine levels and rate of change in testosterone and dehydroepiandrosterone
sulfate (DHEAS) in a cohort of cancer survivors compared to
similar-aged healthy controls.
DESIGN: Prospective cohort.
MATERIALS AND METHODS: Participants were seen for annual visits
that included early follicular phase hormone analyses and pelvic ultrasounds.
Changes in free testosterone, DHEAS, anti-mullerian hormone
(AMH) and antral follicle count (AFC) were modeled over the study
period using random effects linear regression. Exogenous hormone use
was an exclusion criterion.
RESULTS: One hundred and nine cancer survivors (age range 18-39
years, mean 10 years after treatment) and 86 controls were followed
on average for 15 months. The absolute levels of hormones differed between
the groups. In adjusted models, geometric mean (GM) AMH
levels in the cancer survivors at age 30 were 70% lower than in controls
(0.64 ng/mL vs. 2.14 ng/mL, p